Compare NRIX & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIX | VET |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | N/A |
| Metric | NRIX | VET |
|---|---|---|
| Price | $19.18 | $8.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $26.77 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | ★ 4.22% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $83,687,000.00 | ★ $1,445,514,003.00 |
| Revenue This Year | $58.38 | $9.23 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.32 | 30.48 |
| 52 Week Low | $8.18 | $5.14 |
| 52 Week High | $22.50 | $10.49 |
| Indicator | NRIX | VET |
|---|---|---|
| Relative Strength Index (RSI) | 66.53 | 47.89 |
| Support Level | $19.02 | $8.54 |
| Resistance Level | $22.50 | $9.28 |
| Average True Range (ATR) | 1.18 | 0.35 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 52.01 | 22.56 |
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.